{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:24:59Z","timestamp":1757589899252,"version":"3.40.5"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A post hoc analysis was performed using data obtained over eight weeks from 200 Japanese patients with schizophrenia who were switched to brexpiprazole monotherapy in a long\u2010term treatment study. The 8\u2010week period comprised of a 4\u2010week switching phase and a 4\u2010week post\u2010switch phase. For the antipsychotic switching schedule, brexpiprazole was first administered at 1\u00a0mg\/day and increased to 2\u00a0mg\/day by the end of week 4. Concurrently, the previous antipsychotic(s) was\/were tapered gradually from the start of week 3 and discontinued by the end of week 4. Brexpiprazole could then be increased up to 4\u00a0mg\/day according to the CGI\u2010I criteria. At week 8, 1.8%, 23.2%, 25.0%, and 50% of patients were administered daily brexpiprazole doses of 1, 2, 3, and 4\u00a0mg, respectively. The discontinuation rate at week 8 was 17.0%. The major reasons for discontinuation were consent withdrawal (9.5%), occurrence of adverse events (5.5%), and physician's decision (2.0%). Commonly reported adverse events were nasopharyngitis (13.5%), schizophrenia (9.0%), insomnia (6.5%), headache (5.5%), and akathisia (5.5%). The discontinuation rate was 4.9% for patients who were switched from aripiprazole as the primary antipsychotic and 25.4% for those who were switched from other antipsychotics. Owing to the serious adverse events that led to treatment discontinuation, careful switching to brexpiprazole is necessary in patients who previously used olanzapine as their primary antipsychotic.<\/jats:p>","DOI":"10.1002\/npr2.12107","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T05:24:31Z","timestamp":1587014671000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Post\u2010hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long\u2010term study (Secondary Publication)"],"prefix":"10.1002","volume":"40","author":[{"given":"Jun","family":"Ishigooka","sequence":"first","affiliation":[{"name":"Tokyo Women\u2019s Medical University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-8295","authenticated-orcid":false,"given":"Tomohiro","family":"Usami","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-9337","authenticated-orcid":false,"given":"Shuichi","family":"Iwashita","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development Otsuka Pharmaceutical Co., Ltd. Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-8765","authenticated-orcid":false,"given":"Yoshitsugu","family":"Kojima","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-8879","authenticated-orcid":false,"given":"Satoshi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Medical Affairs Otsuka Pharmaceutical Co., Ltd. Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213793"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315614739"},{"issue":"9","key":"e_1_2_10_4_1","first-page":"819","article-title":"Is antipsychotic switching a Copernican change? Purpose and significance of switching to second\u2010generation antipsychotics","volume":"2006","author":"Miyata R","year":"2006","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1013029"},{"key":"e_1_2_10_7_1","first-page":"343","article-title":"Discussion on dosing regimen of a novel antipsychotic, aripiprazole: Experience in the U.K. Jpn","volume":"9","author":"Millar HL","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12654"},{"key":"e_1_2_10_9_1","first-page":"1443","article-title":"Dose equivalence of psychotropic drugs. Part 18: dose equivalence of psychotropic drugs: 2006\u2010version","volume":"9","author":"Inagaki A","year":"2006","journal-title":"Jpn. J Clin Psychopharmacol"},{"key":"e_1_2_10_10_1","unstructured":"Otsuka Pharmaceutical Co. Ltd.Application data for Rexulti. CTD 5.3.5.3\u201005 Table 1.1\u20101 Equivalent doses of antipsychotics used from 30 days before informed consent to the day before hospitalization."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.12.857"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X225448"},{"key":"e_1_2_10_13_1","unstructured":"Otsuka Pharmaceutical Co. Ltd.Rexulti Interview Form (version 2): VII. Pharmacokinetic information April2018."}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnpr2.12107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T05:23:51Z","timestamp":1693977831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/npr2.12107"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12107","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"type":"print","value":"2574-173X"},{"type":"electronic","value":"2574-173X"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2019-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}